文献速递乳腺癌

循环肿瘤细胞与雌激素受体阳性乳腺癌晚期复发的关联:一项随机临床试验的二次分析

Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2018-01-01

该二次分析纳入547例可手术HER2阴性乳腺癌患者,在术后约5年检测循环肿瘤细胞(CTC)。激素受体阳性患者中CTC阳性率为5.1%,CTC阳性与晚期临床复发风险显著相关(HR 13.1,95%CI 4.7-36.3)。表明单次CTC检测可为激素受体阳性乳腺癌晚期复发提供独立预后信息。

要点

  • 术后5年单次CTC阳性与激素受体阳性乳腺癌晚期复发风险升高13.1倍相关。
  • 激素受体阳性患者CTC阳性率5.1%,复发率6.5%。
  • CTC阳性者复发率21.4%/人年,阴性者2.0%/人年。

核心结论

  • 诊断后5年单次CTC检测阳性为激素受体阳性乳腺癌晚期临床复发提供独立预后信息。
  • 液体活检生物标志物可用于晚期复发风险分层并指导治疗。

研究设计与样本

  • 这是一项随机III期试验(多柔比星+环磷酰胺序贯紫杉醇联合贝伐珠单抗或安慰剂)的方案规定二次分析。
  • 纳入2007至2011年入组、原发手术后4.5至7.5年无临床复发证据的HER2阴性II-III期乳腺癌患者。
  • 二次分析子方案入组时间为2013年2月25日至2016年7月29日,分析于2018年4月进行。
  • 共547例女性纳入分析,其中激素受体阳性353例。

主要发现

  • 激素受体阳性患者中CTC检测阳性18/353例(5.1%,95%CI 3.0%-7.9%)。
  • 激素受体阳性患者中临床复发23/353例(6.5%,95%CI 4.2%-9.6%)。
  • CTC阳性组复发率为21.4%/人年(32.7人年7次复发),CTC阴性组为2.0%/人年(796.3人年16次复发)。
  • 多因素模型包括临床协变量,CTC阳性与复发风险升高13.1倍相关(HR 13.1,95%CI 4.7-36.3)。
  • 23例复发患者中7例(30.4%,95%CI 13.2%-52.9%)在临床复发前中位2.8年(范围0.1-2.8年)CTC检测阳性。

关键数值与推荐

  • CTC检测阳性定义为每7.5 mL血液中至少1个CTC。

临床怎么用

  • 对激素受体阳性乳腺癌术后约5年无复发患者,可考虑单次CTC检测进行晚期复发风险分层。
  • CTC阳性者复发风险显著升高,可能需加强随访或考虑辅助治疗干预。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Late recurrence 5 or more years after diagnosis accounts for at least one-half of all cases of recurrent hormone receptor-positive breast cancer. OBJECTIVE: To determine whether the presence of circulating tumor cells (CTCs) in a peripheral blood sample obtained approximately 5 years after diagnosis was associated with late clinical recurrence of operable human epidermal growth factor receptor 2-negative breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This per-protocol secondary analysis of the Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer enrolled patients from 2007 to 2011 who were without clinical evidence of recurrence between 4.5 and 7.5 years after primary surgical treatment of human epidermal growth factor receptor 2-negative stage II-III breast cancer followed by adjuvant systemic therapy. Patients were enrolled in a subprotocol for secondary analysis from February 25, 2013, to July 29, 2016, after signing consent for the subprotocol. The analysis was performed in April 2018. INTERVENTIONS: A blood sample was obtained for identification and enumeration of CTCs. MAIN OUTCOME AND MEASURES: The association between a positive CTC assay result (at least 1 CTC per 7.5 mL of blood) and clinical recurrence. RESULTS: Among 547 women included in this analysis, the results of the CTC assay were positive for 18 of 353 with hormone receptor-positive disease (5.1% [95% CI, 3.0%-7.9%]); 23 of 353 patients (6.5% [95% CI, 4.2%-9.6%]) had a clinical recurrence. The recurrence rates per person-year of follow-up in the CTC-positive and CTC-negative groups were 21.4% (7 recurrences per 32.7 person-years) and 2.0% (16 recurrences per 796.3 person-years), respectively. In multivariate models including clinical covariates, a positive CTC assay result was associated with a 13.1-fold higher risk of recurrence (hazard ratio point estimate, 13.1; 95% CI, 4.7-36.3). Seven of 23 patients (30.4% [95% CI, 13.2%-52.9%]) with recurrence had a positive CTC assay result at a median of 2.8 years (range, 0.1-2.8 years) before clinical recurrence. The CTC assay result was also positive for 8 of 193 patients (4.1% [95% CI, 1.8%-8.0%]) with hormone receptor-negative disease, although only 1 patient (0.5% [95% CI, 0%-2.9%]) experienced disease recurrence (this patient was CTC negative). CONCLUSIONS AND RELEVANCE: A single positive CTC assay result 5 years after diagnosis of hormone receptor-positive breast cancer provided independent prognostic information for late clinical recurrence, which provides proof of concept that liquid-based biomarkers may be used to risk stratify for late recurrence and guide therapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00433511.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Sparano J, O'Neill A, Alpaugh K, et al. Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 30054636. doi:10.1001/jamaoncol.2018.2574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。